Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CCNL2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CCNL2 also known as Cyclin L2 is a protein that plays a role in the regulation of transcription. This protein weighs approximately 59 kDa and contains conserved cyclin domains which aid in its function. It is mainly expressed in tissues like the brain liver and muscle where it performs various regulatory tasks. By interacting with certain kinases CCNL2 helps control the cell cycle's progression particularly during transitions between phases.
Biological function summary
Cyclin L2 modulates transcription processes by associating with splicing factors and RNA polymerase II. It is a part of the spliceosomal complex which influences mRNA processing by ensuring proper splicing of pre-mRNA. This regulation is important for generating diverse and functionally appropriate mRNA transcripts which influences cellular outcome and function. CCNL2's capability to bind with cdk kinases further enhances its role in managing transcription and cell cycle checkpoints within cells.
Pathways
CCNL2 is involved in significant cellular processes such as the cell cycle and mRNA processing pathways. A notable pathway includes the RNA splicing pathway where Cyclin L2 plays a role alongside proteins like cdk kinases which phosphorylate the C-terminal domain to facilitate splicing. Additionally it contributes to the regulation of the cell cycle coordinating with proteins such as cyclin-dependent kinases (CDK) to ensure proper cell cycle progression and division.
Cyclin L2 has associations with cancer and neurological disorders. Abnormal expression or malfunction of CCNL2 can contribute to tumorigenesis potentially through disrupted transcriptional and cell cycle control. In neurological disorders deviations from normal CCNL2 expression levels may impact neuron function and communication. Connections exist between CCNL2 and other proteins implicated in these conditions such as cyclin-dependent kinases which have roles in maintaining cellular homeostasis under normal and disease states.
